PolyActiva Pty Ltd. news
Melbourne, Australia – March 4, 2022 – PolyActiva Pty Ltd, a clinical-stage Australian biopharmaceutical company focused on developing unique biodegradable ocular implants with sustained drug delivery for patients suffering from ophthalmic diseases such as glaucoma, today announced that data from the Phase IIa study of its PA5108 Ocular Implant for the treatment of Primary Open-Angle Glaucoma (POAG) will be presented at the 2022 American Glaucoma Society (AGS) Annual Meeting. The
Melbourne, Australia – February 17, 2022 – PolyActiva Pty Ltd, a clinical-stage Australian biopharmaceutical company focused on developing unique biodegradable ocular implants with sustained drug delivery for patients suffering from ophthalmic diseases such as glaucoma, today announced that the Phase IIa study of its PA5108 Ocular Implant for the treatment of Primary Open-Angle Glaucoma (POAG) met both the study’s primary and secondary efficacy endpoints of at least 20% IOP
Melbourne, 5 November 2020 - PolyActiva Pty Ltd, a clinical-stage Australian ophthalmology biopharmaceutical company, today announced it has successfully completed its Phase I clinical study for its lead candidate, the Latanoprost FA SR Ocular Implant.
The device was well tolerated in all 8 patients with no significant safety findings. The study also showed that the implant persists for the entire 6-month treatment period after which the implant biodegrades completely over six weeks.
Melbourne, Australia - 30 October 2020: PolyActiva Pty Ltd, a clinical-stage ophthalmology biopharmaceutical company, today announced the appointment of highly experienced ophthalmic industry expert, Tracy Valorie, as a new member to the company`s Board of Directors.
Ms Valorie is recognized in the industry for her success in building and leading high performing teams and for her ability to lead commercialization of innovative products in ophthalmology.
Ms Valorie was previously
July 23, Chicago- PolyActiva Pty Ltd, a clinical-stage biotechnology company and leader in ocular drug delivery, has completed patient enrolment for its Phase I clinical trial to study safety and tolerability of its biodegradable, slow-release ocular implant for the treatment of glaucoma.
PolyActiva`s implant has the potential to revolutionise the treatment for millions of glaucoma patients. Current glaucoma treatment requires eye drops to be administered daily, often multiple times e